» Articles » PMID: 9622136

Relaxin Activates the L-arginine-nitric Oxide Pathway in Vascular Smooth Muscle Cells in Culture

Overview
Journal Hypertension
Date 1998 Jun 11
PMID 9622136
Citations 33
Authors
Affiliations
Soon will be listed here.
Abstract

The peptide hormone relaxin (RLX) has been shown to elicit a powerful vasodilatory response in several target organs. This response is mediated by the stimulation of intrinsic nitric oxide (NO) generation. The present study was designed to clarify whether RLX directly promotes the relaxation of vascular smooth muscle cells through stimulation of NO generation. Vascular smooth muscle cells from bovine aortas were incubated with RLX at concentrations ranging from 1 nmol/L to 1 micromol/L. The expression and activity of NO synthase, production of NO, and the intracellular levels of cGMP and Ca2+ were determined. The cell morphology and signal transduction mechanisms of these bovine aortic smooth muscle cells in response to RLX were also studied. RLX stimulated the expression of immunoreactive inducible NO synthase and increased significantly and in a concentration-related fashion inducible NO synthase activity, NO generation, and intracellular cGMP levels. Concurrently, RLX significantly decreased cytosolic Ca2+ concentrations and caused changes in cell shape and the actin cytoskeleton that were consistent with cell relaxation. The signal transduction mechanisms leading to the enhanced expression of inducible NO synthase protein and activity caused by RLX involve the activation of tyrosine kinase, phosphatidylcholine-phospholipase C, and the transcription factor nuclear factor-kappaB, similar to bacterial endotoxins and proinflammatory cytokines. This study suggests that RLX is an endogenous agent capable of regulating vascular tone by activation of the L-arginine-NO pathway in vascular smooth muscle cells.

Citing Articles

Relaxin in fibrotic ligament diseases: Its regulatory role and mechanism.

Yuan S, Guo D, Liang X, Zhang L, Zhang Q, Xie D Front Cell Dev Biol. 2023; 11:1131481.

PMID: 37123405 PMC: 10134402. DOI: 10.3389/fcell.2023.1131481.


The relaxin family peptide receptor 1 (RXFP1): An emerging player in human health and disease.

Chen T, Li X, Hung C, Bahudhanapati H, Tan J, Kass D Mol Genet Genomic Med. 2020; 8(4):e1194.

PMID: 32100955 PMC: 7196478. DOI: 10.1002/mgg3.1194.


Tissue-specific relaxin-2 is differentially associated with the presence/size of an arterial aneurysm and the severity of atherosclerotic disease in humans.

Papoutsis K, Kapelouzou A, Georgiopoulos G, Kontogiannis C, Kourek C, Mylonas K Acta Pharmacol Sin. 2020; 41(6):745-752.

PMID: 32024951 PMC: 7471450. DOI: 10.1038/s41401-019-0350-5.


The Reactivity Levels of Progesterone, Nitric Oxide and Nuclear Factor Kappa-B on the Serum of Term and Post-Term Pregnancy, Clinical Study in Padang, West Sumatera, Indonesia.

Defrin D, Yerizel E, Suhaimi D, Afriwardi A Open Access Maced J Med Sci. 2019; 7(11):1729-1732.

PMID: 31316649 PMC: 6614268. DOI: 10.3889/oamjms.2019.351.


ML290 is a biased allosteric agonist at the relaxin receptor RXFP1.

Kocan M, Sarwar M, Ang S, Xiao J, Marugan J, Hossain M Sci Rep. 2017; 7(1):2968.

PMID: 28592882 PMC: 5462828. DOI: 10.1038/s41598-017-02916-5.